Fablyn Linked to Deaths

The Food and Drug Administration on Thursday concluded that patients treated with an experimental osteoporosis drug were more likely to die than those treated with a placebo. The FDA analysis noted that patients who took the drug Fablyn, produced by Pfizer Inc., showed a statistically significant increase in death and were also more likely to develop blood clots when compared to others in the test group. The FDA is still evaluating the overall safety of the drug. Reuters, Reuters 09/04/2008
Read Article